Defective adenoviruses including a therapeutic gene and an immunoprotectove gene

Patent 6669942 Issued on December 30, 2003. Estimated Expiration Date:

April 15, 2017. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.

Abstract Claims Description Full Text

Inventors

Application

No. 08/817494 filed on 04/15/1997

US Classes:

424/199.1, Recombinant virus encoding one or more heterologous proteins or fragments thereof424/233.1, Adenoviridae, adeno-like virus, or Parvoviridae (e.g., adenovirus, canine parvovirus, mink enteritis virus, hemorrhagic enteritis virus, feline panleukopenia virus, egg drop syndrome virus, etc.)435/320.1, VECTOR, PER SE (E.G., PLASMID, HYBRID PLASMID, COSMID, VIRAL VECTOR, BACTERIOPHAGE VECTOR, ETC.) BACTERIOPHAGE VECTOR, ETC.)435/69.1, Recombinant DNA technique included in method of making a protein or polypeptide536/23.72Viral protein

Examiners

Primary: Salimi, Ali R.

Attorney, Agent or Firm

Wiley Rein & Fielding LLP

International Classes

C12N 15/861 (20060101)
C07K 14/005 (20060101)
C07K 14/075 (20060101)
A61K 48/00 (20060101)

Foreign Application Priority Data

1994-10-17 FR

Abstract

Novel adenovirus-derived viral vectors, the preparation thereof, and the use of such vectors in gene therapy, are disclosed. In particular, defective adenoviruses having a genome that includes a first recombinant DNA containing a therapeutic gene and a second recombinant DNA containing an immunoprotective gene, are disclosed.

Other References

Haddada et al, 1993, Human Gene Theraphy, vol. 4, pp. 703-711.
Rawle et al, 1989, The Journal of Immunology, vol. 143, pp. 2031-2037.
Burgert et al, 1987, PNAS USA, vol. 84, pp. 1356-1360.
Gooding et al, 1988, Cell, vol. 53, pp. 341-346.
Marshall, 1995, Science, vol. 269, pp. 1050-1055.
Orkin et al, 1995, NIH Panel Report on Gene Theraphy.
Kafri et al . PNAS, Sep. 1998, vol. 95, pp. 11377-11382.
Bett et al . PNAS, Sep. 1994, vol. 91, pp, 8802-8806.
Ranheim et al., Characterization of Mutants within the Gene for the Adenovirus E3 14.7-Kilodalton Protein Which Prevents Cytolysis by Tumor Necrosis Factor, J. of Virology, 67(4) p. 2159-2167 (1993)
Kremer et al., Adenovirus and adeno-associated virus mediated gene transfer, British Medical Bulletin 51(1), p. 31-44, (1995)
Lee et al., The constitutive expression of the immunomodulatory gp 19k protein in E1-, E3- adenoviral vectors strongly reduces the host cytotoxic T cell response against the vector, Gene Therapy 2, p. 256-262, (1995)